Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Prostatic Neoplasms × Observation × Clear all

Status

Completed 7 Terminated 3 Recruiting 3 Active not recruiting 3 Unknown 1 Suspended 1

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 3 Stomach Neoplasms 2 Pancreatic Neoplasms 2 Multiple Myeloma 2 Colorectal Neoplasms 2 Tongue Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Recurrence 1 Prostatic Neoplasms 1 Pancreatic Tubular Adenocarcinoma 1 Neoplasms 1 Neoplasm Metastasis 1 Lymphoma, Large B-Cell, Diffuse 1 Infections 1 Hemangioma, Cavernous, Central Nervous System 1 Hemangioma 1 Head and Neck Neoplasms 1 Gallbladder Neoplasms 1 Gallbladder Cancer Unresectable 1 Fallopian Tube Neoplasms 1 Endometrial Neoplasms 1 Colonic Neoplasms 1 Cholangiocarcinoma 1 Carcinoma, Non-Small-Cell Lung 1 Cancer-Related Condition 1 Cachexia 1 Brenner Tumor 1 Biliary Tract Neoplasms 1 Arthritis, Rheumatoid 1

Interventions

Docetaxel 18 Radiosurgery 17 Radiotherapy 14 Androgen Antagonists 14 Leuprolide 11 bicalutamide 9 Goserelin 9 enzalutamide 8 Surveys and Questionnaires 8 Radiotherapy, Intensity-Modulated 7 Prednisone 7 Blood Specimen Collection 7 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 6 Gonadotropin-Releasing Hormone 6 Triptorelin Pamoate 5 Multiparametric Magnetic Resonance Imaging 5 Brachytherapy 5 Abiraterone Acetate 5 Standard of Care 4 Positron Emission Tomography Computed Tomography 4 Metformin 4 Heavy Ion Radiotherapy 4 Exercise 4 Estramustine 4 pembrolizumab 3 luprolide acetate gel depot 3 darolutamide 3 cabazitaxel 3 abiraterone 3 Watchful Waiting 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03893123 2020-03-04

Prostate Cancer Risk in Firefighters

Oslo University Hospital

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡